LLY241227C745000
- 51.47
- +15.62+43.57%
イーライリリー・アンド・カンパニーのニュース一覧
Eli Lilly and Co (LLY) Is Among Billionaire Coleman's Top Picks
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
Eli Lilly's Weight Loss Med Tirzepatide Gets Endorsement From U.K.'s NICE
With EPS Growth And More, Eli Lilly (NYSE:LLY) Makes An Interesting Case
Eli Lilly's Anti-Obesity Drug Mounjaro to Be Supported by UK Public Health System for Some Patients
昨夜,苹果历史新高!
Sector Update: Health Care Stocks Advance Late Afternoon
Ely Lilly Shares Are Trading Higher After the FDA Approved the Company's Zepbound, a Weight Loss Drug Designed to Treat Moderate-to-severe Obstructive Sleep Apnea in Adults With Obesity.
Eli Lilly Stock Is Rising Monday: What's Going On?
Lilly, Amgen Sue HHS Over Certification of Drug Discount Program Recipients
ResMed, Inspire Medical Fall After Lilly's Zepbound Gains Sleep Apnea Indication
Sector Update: Health Care Stocks Fall Premarket Monday
Does Eli Lilly (NYSE:LLY) Deserve A Spot On Your Watchlist?
Lilly's Zepbound Receives FDA Approval for Sleep Apnea
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Eli Lilly's Obesity Drug Wins US Regulatory Nod for Sleep Apnea Treatment
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market